RFC
ARCT icon

Russell Frank Company’s Arcturus Therapeutics ARCT Stock Holding History

Russell Frank Company’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-820
Closed -$100K – 2814
2013
Q4 		$100K Hold
820
– – ﹤0.01% 2666
2013
Q3 		$106K Buy
+820
New +$72.9K ﹤0.01% 2941

Other funds holding ARCT

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
BAAM
Baker Avenue Asset Management San Francisco, California $5.28B AUM 39.19% 1-Year Est. Return

Russell Frank Company's ARCT Position: Q1 2014 in Review

Russell Frank Company sold out of Arcturus Therapeutics (ARCT) in Q1 2014, closing a stake of 820 shares — an estimated $100K sold.

Russell Frank Company first reported a position in ARCT in Q3 2013 and held it in 2 quarters. The position peaked at $106K in Q3 2013. 24 funds tracked by Wall St. Rank hold ARCT as of Q1 2014.

  • Russell Frank Company reported no remaining Arcturus Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Russell Frank Company sold 820 Arcturus Therapeutics shares in Q1 2014, an estimated $100K.
  • Russell Frank Company first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 2 quarters.
  • Russell Frank Company's Arcturus Therapeutics position peaked at $106K in Q3 2013.
  • 24 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2014.

Based on Russell Frank Company's 13F filing for Q1 2014, filed 14 May 2014.